Blue Crest Capital Management LTD Savara Inc Transaction History

Blue Crest Capital Management LTD

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 14, 2019	SELL	$2.16 - $3.2 $68,698 - $101,776	-31,805 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$2.37 - $11.7 $75,377 - $372,118	31,805 New	31,805 $75,000
Q2 2018 Aug 14, 2018	SELL	$8.55 - $13.76 $552,047 - $888,441	-64,567 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$8.99 - $14.95 $366,540 - $609,541	40,772 Added 171.35%	64,567 $594,000
Q4 2017 Feb 14, 2018	BUY	$8.26 - $16.76 $196,546 - $398,804	23,795	23,795 $353,000

129

158M

67.6K

29.4K

Ticker SVRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,043,000
Market Cap $383M
Description
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

Get notified when there are updates to the investment portfolio of Blue Crest Capital Management LTD, based on Form 13F filings with the SEC.

Stay updated on Blue Crest Capital Management LTD with notifications on news.